Metformina + Sitagliptina Sandoz

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metformina + Sitagliptina Sandoz, is a Biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycemic control.

GNH USA supplies Metformina + Sitagliptina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Sandoz is indicated for management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

- Type 2 diabetes mellitus: improves overall glycemic control when used with diet and exercise. - Combination therapy with other oral antidiabetics: provides additional glucose‑lowering effect. - Inadequate control on metformin alone: adds sitagliptin to achieve target HbA1c levels.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Headache: transient tension-type. - Mild hypoglycemia: especially when combined with insulin or sulfonylureas.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: marked low blood glucose requiring assistance. - Pancreatitis: acute inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Hepatic dysfunction: elevated liver enzymes. - Renal impairment: worsening kidney function.

Metformina + Sitagliptina Sandoz should be used with careful clinical monitoring. - Renal function: assess before initiation and monitor regularly. - Hepatic function: evaluate liver enzymes prior to therapy. - Cardiovascular disease: use cautiously in patients with heart failure. - Elderly patients: start at lower dose and monitor for accumulation. - Pregnancy and lactation: only if potential benefit justifies potential risk. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Metformina + Sitagliptina Sandoz may interact with several medicines.

Major Interactions (Avoid): - Severe renal impairment: increased risk of metformin accumulation. - Concomitant use with other DPP‑4 inhibitors: duplicate pharmacologic effect. - Co‑administration with insulin or sulfonylureas: heightened hypoglycemia risk.

Moderate Interactions (Monitor Closely): - Iodinated contrast studies: temporary discontinuation of metformin recommended. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels.